Skip to content

Cogent Biosciences, Inc. COGT Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$310.25M+0.6%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$223.17M
Dropbox logo
DropboxDBX
$690.3M+0.2%
Zscaler logo
ZscalerZS
$1.7B
Commvault Systems logo
Commvault SystemsCVLT
$880.86M
Viavi Solutions Inc. logo
Viavi Solutions Inc.VIAV
$836.3M+111%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s convertible debt (non-current)?
Cogent Biosciences, Inc. (COGT) reported convertible debt (non-current) of $223.17M in Q1 2026.
What does convertible debt (non-current) mean?
This represents the portion of long-term debt obligations that can be converted into equity shares at the holder's option, with a maturity date exceeding one year. It reflects the company's long-term financing strategy and potential future dilution for existing shareholders. Investors analyze this metric to evaluate the company's leverage profile and the potential impact of debt-to-equity conversion on capital structure.